T1	Participants 44 109	children previously randomly assigned to intrathecal methotrexate
T2	Participants 241 283	children with acute lymphoblastic leukemia
T3	Participants 577 750	171 children with standard-risk ALL, age 1 to 9.99 years at diagnosis, previously randomly assigned to IT methotrexate (n = 82) or to triple IT therapy (n = 89) on CCG 1952,
